Pregnancy Category: C
ClassificationTherapeutic: ocular hypotensive agent
Lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Acts as a prostaglandin analogues that decreases intraocular pressure by ↑ uveoscleral outflow.
↓ intraocular pressure.
Absorption: Absorbed through cornea and is converted to the active metabolite tafluprost acid.
Metabolism and Excretion: Further metabolized and eliminated.
Time/action profile (↓ in intraocular pressure)
|Ophth||within 2–4 hr||12 hr||24 hr|
Contraindicated in: Pediatric: Avoid use in children due to unknown safety of chronic ↑ pigmentation.
Use Cautiously in: Aphakia, pseudoaphakia with a torn posterior lens capsule; Known risk factors for macular edema; Obstetric: Women with child-bearing potential should practice adequate contraception; Lactation: Use cautiously in nursing women.
Adverse Reactions/Side Effects
Ear, Eye, Nose, Throat
- conjunctival hyperemia (most frequent)
- blurred vision
- permanent iris pigmentation
- eyelid pigmentation
- lash pigmentation/increased thickness/↑ number
- macular edema
- ocular stinging/irritation
Drug-Drug interactionNote noted.
Ophthalmic (Adults) One drop once daily (into conjunctival sac) in the evening into affected eye(s).
Ophthalmic solution : 0.0015% in 0.3 mL single-use containers
- Measure intraocular pressure periodically during therapy.
Potential Nursing DiagnosesReadiness for enhanced knowledge, related to medication regimen (Patient/Family Teaching)
- Ophthalmic: Wash hands prior to instillation. Pull lower lid downward and look up. Instill 1 drop in conjunctival sac each evening. Each unit is for one-time use; discard after using. Store unopened foil pouches in refrigerator. Do not open pouch until ready to use.
- If used with other ophthalmic medications, administer at least 5 min apart.
- Instruct patient to use drops as directed. Do not use more than 1 drop daily; may increase intraocular pressure. Do not use for a condition for which it was not prescribed. Do not share with others, even if they have the same symptoms; may cause harm.
- Advise patient to read the Patient Information Leaflet prior to initiating therapy and with each Rx refill in case of changes.
- Inform patient of potential side effects including brownish color of the iris; may be permanent. Also, darkening of the eyelid, increasing length, thickness, color, or number of eyelashes, and hair growth on eyelids; usually reversible.
- Advise patient to notify health care professional if eye injury, eye infection, sudden loss of vision, eye surgery, swelling and redness around eye, or problems with eyelids occur.
- Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
- Advise female patient use adequate contraception during therapy and to notify health care professional if pregnancy is planned or suspected, or if breastfeeding.
- Reduction of intraocular pressure.